Ivosidenib Monotherapy Shows Promise in IDH1 Mutated Myelodysplastic Neoplasm/Syndrome: A Phase 2 Study
Highlight
– Ivosidenib (IVO), an oral inhibitor targeting mutant IDH1, was studied as monotherapy in patients with IDH1 mutated myelodysplastic neoplasm/syndrome (MDS).
– The phase 2 trial enrolled 48 patients across three cohorts: high-risk relapsed/refractory post-Azacitidine, treatment-naïve high-risk, and low-risk patients refractory to erythropoiesis-stimulating agents (ESAs).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.